Focus: Quantum Genomics is a Paris-based biotechnology company focused on small molecule development in neurology and respiratory therapeutic areas. The company operates a dual portfolio of generic/ANDA products and early-stage pipeline programs.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
No open roles listed right now. Follow Quantum Genomics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Lead revenue driver (54% of portfolio) but pre-launch status and modest Part D spend suggest early commercialization phase.
Help build intelligence for Quantum Genomics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Quantum Genomics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Established NDA product with incoming patent cliff; Part D revenue declining and near loss of exclusivity.
Pre-launch ANDA in depression market with SSRI/5HT2 antagonist mechanism; revenue potential unclear.
123 discontinued, 17 duplicate formulations not shown
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub